Bulletin of Experimental Biology and Medicine

, Volume 164, Issue 4, pp 483–487 | Cite as

Role of Matrix Metalloproteinase-2 in the Development of Cyclophosphamide-Induced Cardiomyopathy

  • E. V. Koldysheva
  • M. G. Klinnikova
  • D. B. Nikityuk
  • E. K. Ivleva
  • N. A. Listvyagova
  • E. L. Lushnikova
MORPHOLOGY AND PATHOMORPHOLOGY
  • 17 Downloads

Immunohistochemical assay was employed to determine localization of MMP-2 in cardiomyocytes of WAG rats and changes in MMP-2 expression during modeled cardiomyopathy induced by single intraperitoneal injection of cyclophosphamide (125 mg/kg) alone or in combination with preventive intraperitoneal administration of an equal dose of asparcam-L (potassium-magnesium asparaginate) 30 min prior to the cytostatic. In the myocardium of control and experimental rats, MMP-2 was mostly located in cardiomyocyte nuclei. During the development of cyclophosphamide-induced cardiomyopathy (in 3 days after injection), the index of MMP-2-positive cardiomyocyte nuclei increased by 76%. In contrast to control hearts, MMP-2 was also expressed in the cardiomyocyte sarcoplasm. Preventive injection of asparcam-L moderated the cardiotoxic effect of cyclophosphamide, which manifested in less pronounced increase in the volume density of cardiomyocytes with lytic changes (by 42%) and index of MMP-2+ cardiomyocyte nuclei (by 23%) in comparison with the rats exposed to cyclophosphamide alone.

Key Words

cardiomyopathy cyclophosphamide matrix metalloproteinase-2 potassiummagnesium asparaginate immunohistochemistry 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kamyshnikov VS. Reference Book on Clinical and Chemical Laboratory Diagnostics. Vol. 2. Minsk, 2000. Russian.Google Scholar
  2. 2.
    Lushnikova EL, Nikityuk DB, Klinnikova MG, Koldysheva EV, Mzhel’skaya MM. Expression of matrix metalloproteinase-2 in the myocardium in the experimental model of anthracycline cardiomyopathy. Morfologiya. 2016;150(6):29-33. Russian.Google Scholar
  3. 3.
    Nepomnyashchikh LM, Lushnikova EL, Bakarev MA, Nikityuk DB, Yuzhik EI, Mzhelskaya MM, Nepomnyashchikh RD, Klinnikova MG, Karpova AA. Immunohistochemical Analysis of MMP-2 Expression in the Myocardium During the Postinfarction Period. Bull. Exp. Biol. Med. 2015;159(4):505-510.CrossRefPubMedGoogle Scholar
  4. 4.
    Ali MA, Cho WJ, Hudson B, Kassiri Z, Granzier H, Schulz R. Titin is a target of matrix metalloproteinase-2: implications in myocardial ischemia/reperfusion injury. Circulation. 2010;122(20):2039-2047.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Ali MA, Fan X, Schulz R. Cardiac sarcomeric proteins: novel intracellular targets of matrix metalloproteinase-2 in heart disease. Trends Cardiovasc. Med. 2011;21(4):112-118.CrossRefPubMedGoogle Scholar
  6. 6.
    Baghirova S, Hughes BG, Poirier M, Kondo MY, Schulz R. Nuclear matrix metalloproteinase-2 in the cardiomyocyte and the ischemic-reperfused heart. J. Mol. Cell. Cardiol. 2016;94:153-161.CrossRefPubMedGoogle Scholar
  7. 7.
    Bergman MR, Teerlink JR, Mahimkar R, Li L, Zhu BQ, Nguyen A, Dahi S, Karliner JS, Lovett DH. Cardiac matrix metalloproteinase-2 expression independently induces marked ventricular remodeling and systolic dysfunction. Am. J. Physiol. Heart Circ. Physiol. 2007;292(4):H1847-H1860.CrossRefPubMedGoogle Scholar
  8. 8.
    Fan X, Hughes BG, Ali MA, Chan BY, Launier K, Schulz R. Matrix metalloproteinase-2 in oncostatin M-induced sarcomere degeneration in cardiomyocytes. Am. J. Physiol. Heart Circ. Physiol. 2016;311(1):H183-H189.CrossRefPubMedGoogle Scholar
  9. 9.
    Gao L, Zheng YJ, Gu SS, Tan JL, Paul C, Wang YG, Yang HT. Degradation of cardiac myosin light chain kinase by matrix metalloproteinase-2 contributes to myocardial contractile dysfunction during ischemia/reperfusion. J. Mol. Cell. Cardiol. 2014;77:102-112.CrossRefPubMedGoogle Scholar
  10. 10.
    Hughes BG, Fan X, Cho WJ, Schulz R. MMP-2 is localized to the mitochondria-associated membrane of the heart. Am. J. Physiol. Heart Circ. Physiol. 2014;306(5):H764-H770.CrossRefPubMedGoogle Scholar
  11. 11.
    Hughes BG, Schulz R. Targeting MMP-2 to treat ischemic heart injury. Basic Res. Cardiol. 2014;109(4):424. doi:  https://doi.org/10.1007/s00395-014-0424-y.CrossRefPubMedGoogle Scholar
  12. 12.
    Jacob-Ferreira AL, Schulz R. Activation of intracellular matrix metalloproteinase-2 by reactive oxygen-nitrogen species: Consequences and therapeutic strategies in the heart. Arch. Biochem. Biophys. 2013;540(1-2):82-93.CrossRefPubMedGoogle Scholar
  13. 13.
    Schulz R. Intracellular targets of matrix metalloproteinase-2 in cardiac disease: rationale and therapeutic approaches. Annu. Rev. Pharmacol. Toxicol. 2007;47:211-242.CrossRefPubMedGoogle Scholar
  14. 14.
    Spinale FG, Coker ML, Bond BR, Zellner JL. Myocardial matrix degradation and metalloproteinase activation in the failing heart: a potential therapeutic target. Cardiovasc. Res. 2000;46(2):225-238.CrossRefPubMedGoogle Scholar
  15. 15.
    Sung MM, Schulz CG, Wang W, Sawicki G, Bautista-López NL, Schulz R. Matrix metalloproteinase-2 degrades the cytoskeletal protein alpha-actinin in peroxynitrite mediated myocardial injury. J. Mol. Cell. Cardiol. 2007;43(4):429-436.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • E. V. Koldysheva
    • 1
  • M. G. Klinnikova
    • 1
  • D. B. Nikityuk
    • 1
  • E. K. Ivleva
    • 1
  • N. A. Listvyagova
    • 1
  • E. L. Lushnikova
    • 1
  1. 1.Institute of Molecular Pathology and PathomorphologyNovosibirskRussia

Personalised recommendations